Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07300280 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT07300280 is a Phase 1 study of Healthy that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 60 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07300280, a Phase 1 study of Healthy, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.

Conditions Studied

Interventions

  • DRUG Rosuvastatin
  • DRUG Enlicitide
  • DRUG MK-0616A

Study Locations (1)

Arizona

  • Celerion ( Site 0001) - Tempe

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-12-29
Est. Completion 2026-07-22
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

What the Registry Record Tells You About NCT07300280

The ClinicalTrials.gov registry entry for NCT07300280 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Rosuvastatin is the first listed.

NCT07300280 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT07300280 about?

NCT07300280 is a clinical study titled "A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)". This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.

What is the current status of trial NCT07300280?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-12-29. Estimated completion is 2026-07-22.

What conditions does trial NCT07300280 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07300280?

The interventions under investigation include: Rosuvastatin (DRUG), Enlicitide (DRUG), MK-0616A (DRUG).

Who is sponsoring clinical trial NCT07300280?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07300280 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.